According to Y. Zhao et al., there is evidence that trastuzumab-resistant HER2+ breast malignancies have an elevated glycolysis phenotype, and that glycolytic restriction can make these tumours more susceptible to trastuzumab therapy [210]. Here, ERBB2 is linked to neoplasm.